Les Laboratoires Servier

Quantum Genomics

Université´de Rouen

Ipsen Pharma S.a.s.

Innate Pharma

Poxel

Teva Sante

Sidem Pharma Sa

Gérard Coquerel

Barry Victor Lloyd Potter

Jean-Pierre Lecouve

Jean-Marie Schneider

Fabrice Balavoine

Jean-Claude J Souvie

Bruno Pfeiffer

Daniel Cravo

Christian Diolez

Lok Wai Lawrence Woo

Pascal Langlois

Alain Rolland

Julie Linol

Nicolas Couvrat

Guillaume Tauvel

Yohann Cartigny

Loïc Lefebvre

Pascale Authouart

Marie-Noëlle Petit

Avraham Cohen

Suzy Charbit

Jonathan Madec

Olivier Neckebrock

Guillaume Levilain

Adriaan Jan Van Langevelde

Laurent Courvoisier

Franck Patrick Mallet

Sébastien Rose

François Schutze

Matthias Helmreich

Pierre Leproust

Damien Martins

Francis Diancourt

Claus-Peter Niesert

Lionel Le Pape

Marie-Noelle Petit

Stéphane Beilles

Yves-Michel Ginot

Julien Mahieux

Stéphane Bernad

Delphine Delahaye

Youness Amharar

Guillaume Descamps

Pascal Cardinael

Saoussen Wacharine-Antar

Morgane Sanselme

Christine Besselievre

Gilles Serrure

Stéphanie Graf

François-Xavier Gendron

Anaïs Lafontaine

Franck Mallet

The invention relates to the field of resolution of chiral compounds existing in the form of two optical antipodes (enantiomers), such as Baclofen. More particularly, the invention relates to the production of the pure enantiomer (R)(&#x2212;) Baclofen, of chemical nomenclature (R)-4-amino-3-(4-chlorophenyl)-butanoic acid, and the hydrogen maleate salt thereof. More specifically, the invention relates to the resolution of hydrogen maleate salts of racemic Baclofen by preferential crystallisation and particularly by the AS3PC method (auto-seeded and programmed polythermal preferential crystallisation).

Method for resolution of baclofen salts

The present invention relates to a new crystalline phase of (3S,3S') 4,4&#x2032;-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and its use, particularly in the pharmaceutical industry, and to processes for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one crystalline phase of (3S,3S&#x2032;) 4,4&#x2032;-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and to the therapeutic or prophylactic use of such crystalline phase and compositions comprising the same.

Crystalline phase of (3S,3S') 4,4&#x2032;-disulfanediylbis(3-aminobutane 1-sulfonic acid) with L-lysine

The invention relates to a polymorphic form of (&#x2212;)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 &#x212b;, and a process for the preparation thereof.

Process for the preparation of and crystalline forms of optical enantiomers of modafinil

Crystalline phase of (3S.3S') 4,4&#x2032;-disulfanediylbis(3-aminobutane 1-sulfonic acid) with L-lysine

The present invention relates to a new method for the preparation of (3S,3S') 4,4&#x2032;-disulfanediylbis(3-aminobutane 1-sulfonic acid) in five steps from (S)-ethyl 2-(benzyloxycarbonylamino)-4-(neopentyloxysulfonyl)butanoate A.

Method for the preparation of (3S, 3S') 4,4&#x2032;-disulfanediylbis (3-aminobutane 1-sulfonic acid)

A new process for the enantiomeric separation of racemic 3,6-dihydro-1,3,5-triazine derivatives for the treatment of disorders associated with insulin-resistance syndrome, by preferential crystallization.

Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization

The present invention relates to novel polymorphs of (2E)-1-hydroxy-2-methylpent-2-enyl-pyrophosphonate disodium (CHDMAPP-Na), to the process for preparing them and to the pharmaceutical compositions containing them.

Polymorphic form of CHDMAPP, method of preparation thereof, and pharmaceutical composition comprising same

The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound.

Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (C)chromen-3-yl  sulfamate and polymorphs thereof

The invention relates to conglomerates of tenatoprazole potassium salts of the following general formula (I), that consist of an equimolar mixture of enantiomers having R and S configurations and capable of crystallization in the form of a conglomerate, wherein said salts are selected from tenatoprazole dehydrated potassium salt, tenatoprazole potassium dimethanolate, tenatoprazole potassium diethanolate and tenatoprazole potassium ethylene-glycolate. The invention also relates to a pharmaceutical composition containing such salt, and to the use of said salt. 

Conglomerates of tenatoprazole potassium salts

The present invention relates to the resolution by preferential crystallization of potassium salts of racemic omeprazole which is a solvate of ethanol and/or of ethylene glycol, which consists in converting the omeprazole to the potassium salt in the form of a solvate or of a mixture of these solvates in the presence of an excess of inorganic base which is a source of potassium, the said potassium salts existing in the form of conglomerates, and in then resolving the said conglomerates, independently or simultaneously, by preferential crystallization in order to separate the two (S) and (R) enantiomers of these potassium salts of omeprazole.

Method for resolving omeprazole salts

&#x3b2;-crystalline form of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful as inhibitors of angiotensin I converting enzyme.

&#x3b2; Crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it

&#x3b1;-crystalline form of the compound of formula (I): characterized by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful as inhibitors of angiotensin I converting enzyme.

&#x3b1; crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it

A &#x3b2; crystalline form of the compound of formula (I): characterized by its powder X-ray diffraction data. Medicinal products containing the same which are useful as inhibitors of angiotensin I converting enzyme.

&#x3b2; crystalline form of perindopril tert-butylamine salt

Growing community of inventors

Boos, France

Gérard Coquerel